|
Takeda Pharmaceutical Company Limited
|
Home
|
|
-
Antiosteoporotic drugs ?Actonel® 17.5 mg tablets? and ?Benet® 17.5 mg tablets? received approval for additional indication in patients with Paget?s disease of bone: Both come in new packages.
Ajinomoto Co., Inc. (?Ajinomoto?, President and CEO: Norio Yamaguchi, Headquarters: Tokyo) and Takeda Pharmaceutical Company Limited (?Takeda?, President: Yasuchika Hasegawa, Headquarters: Osaka) are pleased to announce that the Ministry of Health, Labour and Welfare (MHLW) has approved the additional indication of ?Actonel® 17.5 mg tablets? and ?Benet® 17.5 mg tablets? (generic name: risedronate sodium hydrate) for Paget?s disease of bone.
-
Notice Concerning the Determination of the Items of Stock Options (Stock Acquisition Rights) for Members of the Board of Directors
Osaka, Japan, July 14, 2008 --- Takeda Pharmaceutical Company Limited (?the Company?) announced today that the amount to be paid in exchange for Stock Acquisition Rights to be granted to its Directors and other related items were decided pursuant to the resolution of the board of directors meeting held on June 26, 2008.
-
Takeda Submitted a Request for Mutual Agreement Procedure Regarding a Correction Notice Based on Transfer Pricing Taxation
Osaka, Japan, July 8, 2008 --- Takeda Pharmaceutical Company Limited ("Takeda") today submitted a request for mutual agreement procedure based on the tax treaty between Japan and the U.S. regarding a correction notice[*1]on transfer pricing taxation from the Osaka Regional Tax Bureau ("ORTB"). On June 28, 2006, Takeda received that notice from the ORTB based on the ORTB's conclusion that the profits earned in the U.S. market in relation to product supply and license transactions on Prevacid[*2], drug for peptic ulcer treatment, between Takeda and TAP Pharmaceutical Products Inc. ("TAP")[*3]were under-allocated to Takeda over the six-year period from fiscal year ending March 2000 through fiscal year ending March 2005. On June 30, 2008 (US Time), TAP was merged by Takeda Pharmaceuticals North America Inc. ("TPNA"), a 100% subsidiary of Takeda America Holdings Inc. which is a wholly owned subsidiary of Takeda located in New York. As a result,TPNA succeeded the rights to Prevacid which had belonged to TAP.
-
Takeda Pharmaceuticals and TAP Pharmaceutical Products Inc. MergeCombined Company is a Top 15 Pharmaceutical Company in the United States
Osaka, Japan and Deerfield, Ill. ? July 1, 2008 (US Time) ? Takeda Pharmaceutical Company Limited today announced that Takeda Pharmaceuticals North America, Inc. and Takeda Global Research & Development Center, Inc. merged with TAP Pharmaceutical Products Inc. (TAP), forming one of the top 15 pharmaceutical companies in the United States.
-
Launch of ?ENBREL® 25mg Syringe 0.5 mL for S.C. Injection?New Formulation of ENBREL®
Tokyo and Osaka, Japan --- June 30, 2008 ? Wyeth K.K. (Wyeth) and Takeda Pharmaceutical Company Limited (Takeda) today announced the launch of ?ENBREL® 25mg Syringe 0.5mL for S.C. Injection,? a new formulation of ENBREL® (generic name: etanercept) for the treatment of rheumatoid arthritis (RA), that is being co-promoted by the two companies.
|
|
Explore the first worldwide Web 2.0 pharmaceutical news portal and 'Vote', 'Comment' or 'Submit' pharmaceutical news articles or other pharmaceutical web resources!
news
European Commission - Pharmaceuticals
US Food and Drug Administration 
